# Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India

> **NCT05020873** · — · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **OTHER:** Crizanlizumab

## Key facts

- **NCT ID:** NCT05020873
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-04
- **Primary completion:** 2023-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05020873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05020873, "Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05020873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*